Compare ETSY & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETSY | APGE |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | 2015 | 2023 |
| Metric | ETSY | APGE |
|---|---|---|
| Price | $53.93 | $83.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 27 | 13 |
| Target Price | $60.00 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $441,231,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $39.08 | ★ N/A |
| Revenue Growth | ★ 20.90 | N/A |
| 52 Week Low | $40.05 | $27.15 |
| 52 Week High | $76.52 | $85.94 |
| Indicator | ETSY | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 61.66 |
| Support Level | $51.09 | $73.06 |
| Resistance Level | $57.22 | N/A |
| Average True Range (ATR) | 2.34 | 4.45 |
| MACD | 0.41 | 0.97 |
| Stochastic Oscillator | 83.23 | 85.91 |
Etsy operates a top-10 e-commerce marketplace in the US and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $12.5 billion in 2024 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. The firm connects about 95 million buyers and 8 million sellers on its marketplace properties: Etsy and Depop (clothing resale).
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.